HWK-016 (MUC16-directed ADC) is a Whitehawk Therapeutics, Inc. program in solid tumors (incl. ovarian cancer). Its next catalyst is a Readout in Q2 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Solid tumors (incl. ovarian cancer). Sponsor: Whitehawk Therapeutics, Inc. (WHWK). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for HWK-016 (MUC16-directed ADC) is a Readout in Q2 2027.
No FDA decision for HWK-016 (MUC16-directed ADC) is in our archive yet.
In our records HWK-016 (MUC16-directed ADC) is under review or in development for Solid tumors (incl. ovarian cancer).
Whitehawk Therapeutics, Inc. (WHWK).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.